Here are four things to know:
1. The higher end of the price target is estimated at $34 while the lower end of the price target is $12, according to the rating issued from 12 Wall Street analysts.
2. The 52-week high of the share price is $29.97 and the 52-week low is $14.71.
3. The company has a market cap of $2,531 million.
4. The company is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.
More articles on GI/endoscopy:
3 GI physicians making headlines – June 5, 2015
PAION begins 2nd phase 3 clinical trial of short acting anesthetic Remimazolam
5 most read GI/endoscopy stories – June 1 to June 5
